Immunoprecise Stock Price, News & Analysis

IPA and Elektrofi are collaborating to develop a low-volume injectable formulation, TATX-03E, of IPA's COVID-19 antibody cocktail, PolyTope® TATX-03. This self-administered formulation aims to provide a stable and easily distributed option for immunodeficient patients requiring ongoing therapy. The collaboration will utilize Elektrofi's technology to enhance delivery methods, supported by a contract from the Department of Defense. The initiative seeks to establish safety and efficacy through IND-enabling studies, with a focus on meeting patient needs and improving access to critical therapies.

ImmunoPrecise Antibodies (NASDAQ: IPA) has partnered with Elektrofi to develop a low-volume self-injectable formulation of its COVID-19 antibody cocktail, PolyTope® TATX-03, now referred to as TATX-03E. This innovative formulation targets immunocompromised patients who require ongoing treatment, allowing for easier at-home administration. Supported by the Department of Defense's SBIR Program, the collaboration will focus on creating an IND-enabling data package for FDA approval, enhancing access to vital therapies for COVID-19 and similar conditions.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reports encouraging results from its latest studies on the PolyTope® TATX-03 antibody cocktail for SARS-CoV-2.

• Animal tests show no acute adverse events, indicating a strong safety profile.
• No pharmacokinetic aberrations were observed.
• Maximum tolerated dose studies revealed no toxicity even at 12.5 times the proposed human dose.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced a conference call scheduled for March 16, 2022, at 10:30 a.m. ET, to discuss its third quarter fiscal year 2022 financial results and recent business highlights. The company will issue a press release before the call, and management will host a question-and-answer session. Investors can submit their questions to John Mullaly of LifeSci Advisors. The call will be available via webcast and can be accessed from the company's investor relations website.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced strong neutralizing data for its PolyTope® TATX-03 antibody cocktail against the SARS-CoV-2 Omicron variant. The company claims TATX-03 is the only first-generation cocktail effective against all tested variants. Following positive in vitro results, IPA plans to submit an Investigational New Drug (IND) application to the FDA. Talem Therapeutics, a subsidiary, filed a patent application for TATX-03, aiming for protection in significant markets. Results indicate potential for broad therapeutic use, even as more variants emerge.

ImmunoPrecise Antibodies Ltd. (IPA) announced the grant of 15,000 stock options to a company officer on January 13, 2022. Each option, priced at Cdn $8.30, allows for the acquisition of up to 15,000 common shares, with a vesting schedule of one-third every two months. This strategic move enhances the company's ability to attract and retain talent while aligning employee interests with shareholder value. ImmunoPrecise focuses on advancing innovative therapeutic antibody discovery to tackle complex disease targets.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced the approval of 170,000 stock options by its board of directors on January 7, 2022. These options are granted to certain officers and are exercisable at Cdn $7.94 per share for five years. The vesting schedule will allow one third of the options to vest every six months. ImmunoPrecise continues to focus on transforming antibody discovery with a comprehensive service suite aimed at optimizing genetic diversity and epitope coverage for its partners.

ImmunoPrecise Antibodies Ltd. (IPA) announces the approval of 28,250 stock options for its non-executive directors, following the recent Annual General Meeting. Each director received 5,650 options, with Ms. Anna Pettersson receiving an additional 11,300 options. The options are exercisable for five years at an exercise price of Cdn $6.89 per share, with quarterly vesting. This action reflects the company’s commitment to rewarding its board members and aligning their interests with shareholders in the dynamic therapeutic antibody sector.